INDUSTRY-SPONSORED SYMPOSIUM | IASLC ASIA
FRIDAY 28TH OCTOBER AT 12:00 – 13:00
ROOM 203, NARA PREFECTURAL CONVENTION CENTER, JAPAN & ONLINE

DECISIVE MOMENTS
IN THE TREATMENT OF
MET EXON 14 SKIPPING NSCLC

Faculty

Prof. Terufumi Kato (Chair)
Kanagawa Cancer Center,
Yokohama, Japan

Prof. Yasushi Goto
National Cancer Center Hospital,
Tokyo, Japan

Prof. Nir Peled
The Institute of Oncology,
Shaare Zedek Medical Center,
Jerusalem, Israel

Prof. James Yang
National Taiwan University
Cancer Center, Taipei, Taiwan

Agenda

A moment to welcome you
Take a moment to consider identification and treatment
Plenary session
A moment of clarity: Has our VISION1 for MET exon 14 skipping become a reality?
Plenary session
A moment to examine treatment outcomes and the VISION1 study in Asian patients
Plenary session
Make every moment matter: Optimizing treatment
Panel discussion
A moment to reflect on MET exon 14 skipping

Audience
Multidisciplinary team members with an interest in the management of patients with MET exon 14 skipping NSCLC

Meeting Objectives
• To highlight the importance of testing for MET exon 14 skipping in patients with NSCLC
• To examine recent evidence describing the efficacy and safety of tepotinib from the VISION1 study
• To share practical insight into the management of these patients during panel discussions

This Industry-Sponsored Symposium is organized and sponsored by Merck Healthcare KGaA.

This program was approved by the IASLC 2022 Asia Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 Asia Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC-accredited program.

Healthcare professionals, please check your locally approved Product Information.